Nu-Med Plus

Nu-Med Plus EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Nu-Med Plus (NUMD) as of Nov 3, 2026 is -48,955.00 USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -63,331.00 USD — a change of -22.70% (higher).

EBITDA

-48,955.00USD

YoY

-22.70%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Nu-Med Plus is 2025 -48,955.00 USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Nu-Med Plus was 2024 -63,331.00 USD. It decreases by -22.70% higher compared to the previous year.

The Nu-Med Plus EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-1.15 M USD
Jan 1, 2019
-1.01 M USD
Jan 1, 2020
-1.98 M USD
Jan 1, 2021
-830,045.00 USD
Jan 1, 2022
-179,867.00 USD
Jan 1, 2023
-120,526.00 USD
Jan 1, 2024
-63,331.00 USD
Jan 1, 2025
-48,955.00 USD
The Nu-Med Plus EBITDA history
YEAREBITDAYoY
-48,955.00USD-22.70%
-63,331.00USD-47.45%
-120,526.00USD-32.99%
-179,867.00USD-78.33%
-830,045.00USD-58.14%
-1.98 MUSD+97.10%
-1.01 MUSD-12.87%
-1.15 MUSD-100.53%
216.11 MUSD+5.42%
204.99 MUSD+75.07%
117.09 MUSD-10,378.82%
-1.14 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Nu-Med Plus Stock analysis

What does Nu-Med Plus do? Nu-Med Plus Inc is a US company specializing in the development of medical devices and technologies. The company was founded in 2011 by Cameron Wakefield and is headquartered in Salt Lake City, Utah. Nu-Med Plus' business model is based on the development of innovative solutions for healthcare and medical equipment. The company focuses mainly on the development of medical gases and specifically nitric oxide technologies. As a leader in nitric oxide technology, Nu-Med Plus offers a variety of products. These include devices for the administration of nitric oxide, such as the Nu-Med Plus Nitric Oxide Delivery System, which allows for precise dosage of nitric oxide. In addition, the company has also developed a range of products based on the use of nitric oxide. These include nasal sprays for the treatment of angina and other heart conditions, as well as inhalable medications for the treatment of acute asthma. However, Nu-Med Plus is not only specialized in nitric oxide technologies. The company has also developed devices and technologies targeting other areas of healthcare. These products include the Nu-Med Plus Portable Oxygen Concentrator, a portable oxygen concentrator system, and the Nu-Med Plus Wireless Vital Sign Monitoring System, a wireless technology for real-time monitoring of patients' vital signs. Furthermore, Nu-Med Plus has formed partnerships with other companies in the medical industry, allowing the company to expand its range of products and services and enhance its commitment to medical research and development. In the fiscal year 2020, Nu-Med Plus generated approximately $2.7 million in revenue and employed about 15 employees. With the increasing need for innovative medical solutions and the growing demand for medical gases and nitric oxide technologies, the company remains optimistic about its ability to continue its growth in the coming years. Overall, Nu-Med Plus is a leading company in the field of medical devices and technologies. With its innovative research and development and strong partnerships, the company offers a wide range of products that can contribute to improving the quality of healthcare and making the lives of patients around the world easier. Nu-Med Plus is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Nu-Med Plus stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Nu-Med Plus is -48,955.00 USD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Nu-Med Plus changed from -63,331.00 USD to -48,955.00 USD, representing a -22.70% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Nu-Med Plus since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Nu-Med Plus historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Nu-Med Plus

All Key Metrics — Nu-Med Plus